These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 36091687)

  • 1. Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma.
    Li Z; Wang W; Wu J; Ye X
    Front Med (Lausanne); 2022; 9():962972. PubMed ID: 36091687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
    Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
    Front Genet; 2022; 13():1017866. PubMed ID: 36699466
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anoikis-related subtype and prognosis analyses based on bioinformatics, and an expression verification of ANGPTL4 based on experiments of lung adenocarcinoma.
    Shen X; Xie J; Liu S; Cai Y; Yuan S; Uehara Y; Zhu D; Zheng M
    J Thorac Dis; 2024 Aug; 16(8):5361-5378. PubMed ID: 39268091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
    Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
    Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis-Related Signature Predicts Prognosis and Immune Microenvironment Infiltration in Lung Adenocarcinoma.
    Zou X; He R; Zhang Z; Yan Y
    Front Genet; 2022; 13():818403. PubMed ID: 35571020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of natural killer cell associated subtyping and gene signature to predict prognosis and drug sensitivity of lung adenocarcinoma.
    Zhang D; Zhao Y
    Front Genet; 2023; 14():1156230. PubMed ID: 37091780
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic Value and Immune Landscapes of Four Types of RNA Modification Writer-Related LncRNAs Signature in Lung Adenocarcinoma.
    Qian Y; Zhang Q; Ren Y; Cao L; Zheng S; Li B; Wu X; Meng Z; Xu K
    J Cancer; 2024; 15(15):4818-4837. PubMed ID: 39132150
    [No Abstract]   [Full Text] [Related]  

  • 14. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
    Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Risk Model Developed based on Homologous Recombination Deficiency Genes for Evaluating the Drug Sensitivity and Prognostic Prediction of Lung Adenocarcinoma.
    Hong L; Li J; Shao W
    Curr Med Chem; 2024 Oct; ():. PubMed ID: 39354765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
    Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
    Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Analysis and Identification of Molecular Subtypes of TRP-Related Genes and Prognosis Prediction in Lung Adenocarcinoma.
    Guo Y; Liu N
    J Oncol; 2022; 2022():5388283. PubMed ID: 36090899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of lung adenocarcinoma subtypes and a prognostic signature based on activity changes of the hallmark and immunologic gene sets.
    Zhou SK; Zeng DH; Zhang MQ; Chen MM; Liu YM; Chen QQ; Lin ZY; Yang SS; Fu ZC; Lian DH; Ying WM
    Heliyon; 2024 Apr; 10(7):e28090. PubMed ID: 38571596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of polyamine metabolism predicts prognosis, immune profile, and therapeutic efficacy in lung adenocarcinoma patients.
    Li Z; Wu Y; Yang W; Wang W; Li J; Huang X; Yang Y; Zhang X; Ye X
    Front Cell Dev Biol; 2024; 12():1331759. PubMed ID: 38650895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.